Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: An airport runway arrangement for commercial aircraft comprises a first runway section, a second runway section extending substantially in prolongation of the first runway section and an intermediate section between the first and second runway sections.

Abstract: A runway arrangement comprising: a first runway section (202-1) designated as a landing runway section; a second runway section (202-2) designated as a take-off runway section; and a sterile safety area (210); wherein the first and second runway sections are linked by the sterile safety area (210); the runway arrangement comprising a missed approach point for aircraft due to land on the first runway section, displaced from the start of the second runway section (202-2) by a distance greater than H/tan ?1; where H is a safe turning height and ?1 is an angle of ascent following a missed approach; wherein H is greater than 150 m and ?1 is greater than 2°.

Abstract: A runway arrangement comprising: a first runway section (202-1) designated as a landing runway section; a second runway section (202-2) designated as a take-off runway section; and a sterile safety area (210); wherein the first and second runway sections are linked by the sterile safety area (210); the runway arrangement comprising a missed approach point for aircraft due to land on the first runway section, displaced from the start of the second runway section (202-2) by a distance greater than H/tan ?1; where H is a safe turning height and ?1 is an angle of ascent following a missed approach; wherein H is greater than 150 m and ?1 is greater than 2°.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: An airport runway arrangement for commercial aircraft comprises a first runway section, a second runway section extending substantially in prolongation of the first runway section and an intermediate section between the first and second runway sections.

Abstract: A runway arrangement comprising: a first runway section (202-1) designated as a landing runway section; a second runway section (202-2) designated as a take-off runway section; and a sterile safety area (210); wherein the first and second runway sections are linked by the sterile safety area (210); the runway arrangement comprising a missed approach point for aircraft due to land on the first runway section, displaced from the start of the second runway section (202-2) by a distance greater than H/tan ?1; where H is a safe turning height and ?1 is an angle of ascent following a missed approach; wherein H is greater than 150 m and ?1 is greater than 2°.

Abstract: A device for marking a runway section, the device comprising: a light source; and a light director.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: In one or more embodiments, a storage system is provided for use with a vehicle including a side wall and a rear wheel positioned below the side wall; the storage system includes a storage container receivable within an elongated space defined between inboard and outboard panels of the side wall, the storage container including front and rearward portions respectively positioned front and rear to the rearmost point of the rear wheel. The storage system may further include a leg portion for supporting the rearward portion of the storage container. The leg portion may be adjustable in length and may be attached to the elongated space or to the storage container.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.

Abstract: Methods and systems are provided for a vapor canister couple to a fuel tank of a vehicle. A series of fluidically coupled, variable capacity bleed elements, externally coupled to a sidewall of the vapor canister, capture the bleed emissions resulting from desorption of fuel vapors from an adsorbent material inside the vapor canister. The series of bleed elements may be fluidically coupled through flow paths passing through the vapor canister wall, connecting through a first flow path to a chamber inside the vapor canister and connecting through a second flow path to a vent port of the vapor canister.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Methods and systems are provided for a vapor canister couple to a fuel tank of a vehicle. A series of fluidically coupled, variable capacity bleed elements, externally coupled to a sidewall of the vapor canister, capture the bleed emissions resulting from desorption of fuel vapors from an adsorbent material inside the vapor canister. The series of bleed elements may be fluidically coupled through flow paths passing through the vapor canister wall, connecting through a first flow path to a chamber inside the vapor canister and connecting through a second flow path to a vent port of the vapor canister.

Abstract: A device for marking a runway section, the device comprising: a light source; and a light director.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.